Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2023-10-13 00:00:00 ET · period of report 2023-10-11 · accession 0000950170-23-053381 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-13 | 2023-10-11 | INKT | Buell Jennifer | CEO, Dir | J - Other | — | -695.8K | 232.2K | -75% | — |
| D | 2023-10-13 | 2023-10-11 | INKT | Buell Jennifer | CEO, Dir | A - Grant | $0.00 | -695.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-11 | J | D | 695,750 | — | 232,165 | D | — | — | (F1) Dr. Jennifer Buell was awarded Restricted Stock Units ("RSUs") which corresponded to 695,750 shares of MiNK Therapeutics, Inc. ("Company") common stock ("Common Stock"). These RSUs, tied to the Company's Initial Public Offering ("IPO"), vested on September 27, 2023. Dr. Buell previously reported on Form 4s the receipt of such shares of Common Stock (the "RSU Shares") and subsequent sales of shares of Common Stock to cover Federal, state and local tax withholding requirements. However, the Company and Dr. Buell agreed that it is in the best interests of the Company and its stockholders for Dr. Buell to forfeit that award in lieu of a new award that will vest over a period of five years (see Explanation of Responses #2). Therefore Dr. Buell is returning the RSU Shares to the Company. Dr Buell has thus made the Company whole for the forfeited award by returning 695,750 shares of Company Common Stock to the Company on October 11, 2023 for no consideration. |
| 2 | Derivative | Restricted Stock Units | 2023-10-11 | A | D | 695,750 | $0.00 | 0 | D | — · — to — | 695,750 Common Stock | (F2) On October 11, 2023, in alignment with the Company's 2021 Equity Incentive Plan, Dr. Buell received a grant of 695,750 RSUs. This new grant serves as a replacement for the RSUs initially awarded during the Company's IPO, which Dr. Buell forfeited and returned to the Company on October 11, 2023. These newly granted RSUs will vest over a five-year period, with one-third of the restricted stock units vesting on each of the third, fourth and fifth anniversaries of the grant date. |